Placebo for prednisolone

DRUG2 trials

Sponsors

Glaxosmithkline Research & Development Limited, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Acute Liver FailureAcute Liver InjuryFulminant Hepatic FailureHepatic EncephalopathyHypereosinophilic Syndrome (HES)Immune Dysregulation

Phase 2

TReatment for ImmUne Mediated PathopHysiology

RecruitingNCT04862221

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Acute Liver Failure, Acute Liver Injury, Fulminant Hepatic Failure +2

Start: 2022-02-09End: 2027-02-01Target: 163Updated: 2026-03-10

Phase 3

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES)

RecruitingCTIS2023-510346-25-00

Glaxosmithkline Research & Development LimitedHypereosinophilic Syndrome (HES)

Start: 2022-09-01Target: 36Updated: 2025-12-10